Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3Thoracic 1Other solid neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Classical hematology 1

Conditions

Pancreatic Neoplasms 1Mesothelioma 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 41Injections 39toripalimab 23Nivolumab 22Cisplatin 19Pemetrexed 18Carboplatin 18Cyclophosphamide 17Paclitaxel 14Bevacizumab 14fludarabine 12Gemcitabine 11tislelizumab 10Ipilimumab 10spartalizumab 9Irinotecan 9atezolizumab 8Docetaxel 8Oxaliplatin 7Leucovorin 7Fluorouracil 7Capecitabine 6sintilimab 5Interleukin-2 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5trifluridine tipiracil drug combination 4sotorasib 4pazopanib 4palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pentostatin × Other solid neoplasm × Clear all
NCT01362790 2019-06-06

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
55 enrolled 22 charts
GastrointestinalOther solid neoplasmThoracic

Adenocarcinoma of Lung, Mesothelioma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡